Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
72 hedge funds and large institutions have $59.8M invested in Paratek Pharmaceuticals, Inc. in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 16 closing their positions.
158% more call options, than puts
Call options by funds: $411K | Put options by funds: $159K
35% more capital invested
Capital invested by funds: $44.4M → $59.8M (+$15.4M)
15% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 20
14% less funds holding
Funds holding: 84 → 72 (-12)
69% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.24M |
| 2 |
JGC
J. Goldman & Co
New York
|
+$1.09M |
| 3 |
BlackRock
New York
|
+$831K |
| 4 |
Two Sigma Advisers
New York
|
+$703K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$643K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIG
Fortress Investment Group
New York
|
-$1.56M |
| 2 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$930K |
| 3 |
Millennium Management
New York
|
-$523K |
| 4 |
TI
Telemetry Investments
New York
|
-$373K |
| 5 |
E
Ergoteles
New York
|
-$297K |
PRTK Hedge Fund Activity: Q3 2022 in Review
72 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q3 2022, worth a combined $59.8M — up 35% from $44.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of PRTK and 5 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 23 added.
The largest buyer was AIGH Capital Management, adding an estimated $1.24M. The largest seller was Fortress Investment Group, exiting entirely with an estimated $1.56M sold.
- 72 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q3 2022, down from 84 in Q2 2022.
- Funds reported $59.8M of Paratek Pharmaceuticals, Inc. stock for Q3 2022, up 35% quarter-over-quarter.
- 5 funds opened new Paratek Pharmaceuticals, Inc. positions in Q3 2022 and 16 closed out, a net change of -11 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q3 2022 was AIGH Capital Management, an estimated $1.24M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q3 2022 was Fortress Investment Group, an estimated $1.56M sold.
Based on aggregated 13F filings for Q3 2022.